Tvardi Therapeutics
TVRD
101 hedge funds and large institutions have $129M invested in Tvardi Therapeutics in 2016 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 12 closing their positions.
205% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $583K
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
35% more capital invested
Capital invested by funds: $95.5M → $129M (+$33.4M)
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
25% more funds holding
Funds holding: 81 → 101 (+20)
1.41% more ownership
Funds ownership: 0% → 1.41% (+1.4%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$7.92M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.67M |
| 3 |
NC
Nexthera Capital
New York
|
+$2.23M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$2.14M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.33M |
| 2 |
Renaissance Technologies
New York
|
-$2.07M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.78M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$1.05M |
| 5 |
Morgan Stanley
New York
|
-$897K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
101
Renaissance Technologies
New York
| – | -$2.07M | -6,886 | Closed |
|
|
EMG
102
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$780K | -2,594 | Closed |
|
|
PAM
103
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$369K | -1,229 | Closed |
|
104
AQR Capital Management
Greenwich,
Connecticut
| – | -$349K | -1,163 | Closed |
|
|
GCP
105
GSA Capital Partners
London,
United Kingdom
| – | -$327K | -1,089 | Closed |
|
|
VKH
106
Virtu KCG Holdings
New York
| – | -$248K | -824 | Closed |
|
107
Jane Street
New York
| – | -$235K | -732 | Closed |
|
108
ProShare Advisors
Bethesda,
Maryland
| – | -$161K | -536 | Closed |
|
|
HCM
109
Highbridge Capital Management
New York
| – | -$105K | -348 | Closed |
|
110
Tudor Investment Corp
Stamford,
Connecticut
| – | -$104K | -346 | Closed |
|
|
PHK
111
Point72 Hong Kong
Hong Kong
| – | -$31K | -103 | Closed |
|
|
NFG
112
Next Financial Group
Houston,
Texas
| – | -$2K | -7 | Closed |
|
TVRD Hedge Fund Activity: Q4 2016 in Review
101 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2016, worth a combined $129M — up 35% from $95.5M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TVRD positions and 12 closed out — a net gain of 20 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was Disciplined Growth Investors, opening a new position worth an estimated $7.92M. The largest seller was BlackRock Fund Advisors, cutting an estimated $2.33M.
- 101 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2016, up from 81 in Q3 2016.
- Funds reported $129M of Tvardi Therapeutics stock for Q4 2016, up 35% quarter-over-quarter.
- 32 funds opened new Tvardi Therapeutics positions in Q4 2016 and 12 closed out, a net change of +20 holders.
- The largest Tvardi Therapeutics buyer in Q4 2016 was Disciplined Growth Investors, an estimated $7.92M added.
- The largest Tvardi Therapeutics seller in Q4 2016 was BlackRock Fund Advisors, an estimated $2.33M sold.
Based on aggregated 13F filings for Q4 2016.